Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.69
(-0.74%)
CNY 2.69
(-0.74%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 674.86 Million CNY | -53.62% |
| 2022 | 1.45 Billion CNY | -6.62% |
| 2021 | 1.55 Billion CNY | 15.21% |
| 2020 | 1.35 Billion CNY | -49.49% |
| 2019 | 2.67 Billion CNY | -14.18% |
| 2018 | 3.11 Billion CNY | -12.62% |
| 2017 | 3.57 Billion CNY | -4.02% |
| 2016 | 3.71 Billion CNY | 2.83% |
| 2015 | 3.61 Billion CNY | 280.41% |
| 2014 | 950.99 Million CNY | 0.0% |
| 2013 | - CNY | -100.0% |
| 2012 | 25 Million CNY | -16.67% |
| 2011 | 30 Million CNY | 0.0% |
| 2010 | - CNY | -100.0% |
| 2009 | 92 Million CNY | 76.92% |
| 2008 | 52 Million CNY | 44.16% |
| 2007 | 36.07 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 425.45 Million CNY | -36.96% |
| 2024 Q2 | 115.03 Million CNY | -72.96% |
| 2024 Q3 | 43.53 Million CNY | -58.96% |
| 2023 Q3 | 800.9 Million CNY | -20.0% |
| 2023 Q4 | 674.86 Million CNY | -15.74% |
| 2023 FY | 674.86 Million CNY | -53.62% |
| 2023 Q1 | 1.37 Billion CNY | -5.65% |
| 2023 Q2 | 1 Billion CNY | -27.08% |
| 2022 Q3 | 1.55 Billion CNY | 0.0% |
| 2022 FY | 1.45 Billion CNY | -6.62% |
| 2022 Q4 | 1.45 Billion CNY | -6.61% |
| 2022 Q2 | 1.55 Billion CNY | -0.01% |
| 2022 Q1 | 1.55 Billion CNY | -0.0% |
| 2021 FY | 1.55 Billion CNY | 15.21% |
| 2021 Q4 | 1.55 Billion CNY | -6.09% |
| 2021 Q1 | 1.62 Billion CNY | 19.84% |
| 2021 Q2 | 1.65 Billion CNY | 2.37% |
| 2021 Q3 | 1.65 Billion CNY | 0.0% |
| 2020 Q2 | 1.89 Billion CNY | -5.97% |
| 2020 Q4 | 1.35 Billion CNY | -20.0% |
| 2020 FY | 1.35 Billion CNY | -49.49% |
| 2020 Q1 | 2.01 Billion CNY | -24.92% |
| 2020 Q3 | 1.69 Billion CNY | -10.56% |
| 2019 Q1 | 2.99 Billion CNY | -3.94% |
| 2019 FY | 2.67 Billion CNY | -14.18% |
| 2019 Q4 | 2.67 Billion CNY | -9.58% |
| 2019 Q3 | 2.96 Billion CNY | -0.62% |
| 2019 Q2 | 2.97 Billion CNY | -0.57% |
| 2018 Q4 | 3.11 Billion CNY | -2.27% |
| 2018 Q3 | 3.19 Billion CNY | -5.95% |
| 2018 FY | 3.11 Billion CNY | -12.62% |
| 2018 Q1 | 3.62 Billion CNY | 1.64% |
| 2018 Q2 | 3.39 Billion CNY | -6.47% |
| 2017 Q4 | 3.57 Billion CNY | -7.73% |
| 2017 FY | 3.57 Billion CNY | -4.02% |
| 2017 Q1 | 3.7 Billion CNY | -0.33% |
| 2017 Q2 | 3.82 Billion CNY | 3.13% |
| 2017 Q3 | 3.86 Billion CNY | 1.2% |
| 2016 Q2 | 3.7 Billion CNY | 4.33% |
| 2016 Q1 | 3.55 Billion CNY | -1.86% |
| 2016 Q4 | 3.71 Billion CNY | -1.02% |
| 2016 Q3 | 3.75 Billion CNY | 1.47% |
| 2016 FY | 3.71 Billion CNY | 2.83% |
| 2015 Q1 | 2.64 Billion CNY | 178.36% |
| 2015 FY | 3.61 Billion CNY | 280.41% |
| 2015 Q3 | 3.02 Billion CNY | 11.66% |
| 2015 Q4 | 3.61 Billion CNY | 19.43% |
| 2015 Q2 | 2.71 Billion CNY | 2.48% |
| 2014 Q4 | 950.99 Million CNY | 98.12% |
| 2014 Q3 | 480 Million CNY | -23.81% |
| 2014 FY | 950.99 Million CNY | 0.0% |
| 2014 Q1 | 200 Million CNY | 0.0% |
| 2014 Q2 | 630 Million CNY | 215.0% |
| 2013 Q2 | 20 Million CNY | -20.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 FY | - CNY | -100.0% |
| 2013 Q1 | 25 Million CNY | 0.0% |
| 2013 Q3 | - CNY | -100.0% |
| 2012 Q4 | 25 Million CNY | -9.09% |
| 2012 FY | 25 Million CNY | -16.67% |
| 2012 Q3 | 27.5 Million CNY | 0.0% |
| 2012 Q2 | 27.5 Million CNY | -8.33% |
| 2012 Q1 | 30 Million CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2011 Q4 | 30 Million CNY | 0.0% |
| 2011 FY | 30 Million CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 Q2 | 92 Million CNY | 0.0% |
| 2010 Q3 | 42 Million CNY | -54.35% |
| 2010 Q4 | - CNY | -100.0% |
| 2010 FY | - CNY | -100.0% |
| 2010 Q1 | 92 Million CNY | 0.0% |
| 2009 Q4 | 92 Million CNY | 0.0% |
| 2009 FY | 92 Million CNY | 76.92% |
| 2008 FY | 52 Million CNY | 44.16% |
| 2007 FY | 36.07 Million CNY | 0.0% |